[177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|3|1|29-36

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.3, Iss.1, 2010-01, pp. : 29-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Octreotate-Lu-177-DOTA-Tyr-3: First report of hormonal crises: 6 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1207, 2008-01 ,pp. : 26-27

Adis International

Access to resources Recommend Favorite

Octreotate-Lu-177-DOTA-Tyr-3/yttrium-90-DOTATOC: Acute myeloid leukaemia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1401, 2012-01 ,pp. : 28-29

Adis International

Access to resources Recommend Favorite

Overview of Development and Formulation of 177Lu-DOTA-TATE for PRRT

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 8-18

Bentham Science Publishers

Access to resources Recommend Favorite

A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu-DOTA-Nimotuzumab

By  

Current Radiopharmaceuticals, Vol. 5, Iss. 4, 2012-10 ,pp. : 318-324

Bentham Science Publishers

Access to resources Recommend Favorite

Estimation of specific activity of 177Lu by `saturation assay` principle using DOTA as ligand

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 123-128

Bentham Science Publishers

Access to resources Recommend Favorite